Biotechnology company Moderna Inc (Nasdaq:MRNA) reported on Wednesday the completion of the manufacturing of clinical trial material for its variant-specific vaccine candidate mRNA-1273.351 against the SARS-CoV-2 variant (B.1.351) first identified South Africa.
In conjunction, the company has shipped the doses of mRNA-1273.351 vaccine candidate to the National Institutes of Health (NIH) for a Phase 1 clinical trial that will be led and funded by the NIH's National Institute of Allergy and Infectious Diseases (NIAID).
Subject to US FDA's review, the company plans to evaluate a variant-specific booster candidate mRNA-1273.351 based on the B.1.351 variant first identified in South Africa at the 50 µgdose level and lower, a multivalent booster candidate mRNA-1273.211 in a single vaccine at the 50µg dose level and lower as well as a third dose of mRNA-1273 as a booster at the 50µg dose level.
According to the company, it intends to evaluate mRNA-1273.351 and mRNA-1273.211 as a primary vaccination series for those who are seronegative in a two-dose series at the 100µg dose level and lower.
Based on the updated US FDA guidance for Industry, the company proposes to evaluate immunogenicity and safety in participants who have not received a COVID-19 vaccine as well as participants in clinical studies who previously received the mRNA-1273 vaccine.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100